TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05961319

Intervention type: DEVICE
Intervention: Smart-Home Monitoring
Description: During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study.
Study: NCT05294640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eyelid Lesion Removal
Description: Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Lesion Removal
Description: Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
Study: NCT06568900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cigarette smoking
Description: continue smoking usual brand of cigarette

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tobacco flavored and unflavored pouch
Description: provide tobacco flavored and unflavored options of nicotine pouch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: unrestricted flavor options pouch
Description: provide unrestricted flavor options of nicotine pouch
Study: NCT06542887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Seed Oil Cap/Tab
Description: Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
Study: NCT04671303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets
Description: Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle.
Study: NCT06390111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadofaragene firadenovec
Description: The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
Study: NCT05553600

Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon BR
Description: Modified Regular Absorbency Tampons

Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon CR
Description: Reference Regular Absorbency Tampons

Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon BS
Description: Modified Super Absorbency Tampons

Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon CS
Description: Reference Super Absorbency Tampons
Study: NCT05229562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.
Study: NCT06159894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAY HOSPITAL ARM
Description: The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist-Care arm
Description: The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice.
Study: NCT06060405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
Study: NCT06368128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Rock Climbing Exercise Training Program
Description: Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
Study: NCT05797779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Punch biopsy of the skin
Study: NCT05913297

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance
Description: Magnetic Resonance

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance
Description: Magnetic Resonance

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnographic evaluation
Description: Polysomnographic evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnographic evaluation
Description: Polysomnographic evaluation
Study: NCT04892901

Intervention type: PROCEDURE
Intervention: c-ESPB
Description: In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.

Intervention type: PROCEDURE
Intervention: c-SAPB
Description: In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.

Intervention type: PROCEDURE
Intervention: ICNB
Description: In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump.
Study: NCT05902195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Resource Building and Inclusive Volunteering Intervention (PVI)
Description: PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
Study: NCT06097052

Intervention type: DEVICE
Intervention: Hypotension Predictive Index
Description: Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
Study: NCT06038877

Intervention type: OTHER
Intervention: Interviews
Description: Individual semi-structured interviews

Intervention type: OTHER
Intervention: Qualitative analysis
Description: Thematic analysis of the content of responses
Study: NCT06534736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy and physical agents
Description: It will comprise of hot pack for 10 minutes, Tens for 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy and physical agents
Description: It will comprise of hot pack for 10 minutes, Tens for 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization Exercise
Description: Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
Study: NCT06097039

Intervention type: DEVICE
Intervention: abdominal U/S
Description: A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.

Intervention type: DEVICE
Intervention: abdominal U/S
Description: A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.

Intervention type: DEVICE
Intervention: Fibroscan with Controlled Attenuated Parameter (CAP scan):
Description: Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m).

Intervention type: DEVICE
Intervention: Fibroscan with Controlled Attenuated Parameter (CAP scan):
Description: Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m).
Study: NCT06270459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMAN Robot
Description: The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
Study: NCT05057767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam injection
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
Study: NCT05548543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.
Study: NCT06117566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks
Study: NCT06117566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks
Study: NCT06133907

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Serum
Description: Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
Study: NCT05658692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedative analgesia/muscle relaxant therapy
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotropes therapy
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Study: NCT05110144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: 30mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: 30mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: 60mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 MG
Description: 25 mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 MG
Description: 25 mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 MG
Description: 50 mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 60 MG
Description: 60mg tablet with no active study ingredient for 4 weeks
Study: NCT06419855

Intervention type: DEVICE
Intervention: Human collagen matrix graft
Description: Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.

Intervention type: DEVICE
Intervention: Bovine collagen matrix graft
Description: Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
Study: NCT05877235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Trans-quercetin, 1000 mg daily for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Trans-quercetin, 1000 mg daily for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch, 1000 mg daily for 60 days
Study: NCT05805956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2902
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Study: NCT05057767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
Study: NCT05658692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoactive drug therapy
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Study: NCT05576285

Intervention type: DIAGNOSTIC_TEST
Intervention: ophthalmoscopy and fundus photography through dilated pupills
Description: ophthalmoscopy and fundus photography through dilated pupills
Study: NCT05486039

Intervention type: BEHAVIORAL
Intervention: Changing behaviour
Description: Changing the lying position and mattress system
Study: NCT05576285

Intervention type: DIAGNOSTIC_TEST
Intervention: ophthalmoscopy and fundus photography through dilated pupills
Description: ophthalmoscopy and fundus photography through dilated pupills

Intervention type: DIAGNOSTIC_TEST
Intervention: ophthalmoscopy and fundus photography through dilated pupills
Description: ophthalmoscopy and fundus photography through dilated pupills
Study: NCT04776629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orticumab
Description: A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for orticumab, containing all components of formulation except the active ingredient
Study: NCT05382208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally twice a day.
Study: NCT06060561

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study